Petronijević, Marija

Link to this page

Authority KeyName Variants
e4f78d22-0c76-4439-9889-7a68f984d05e
  • Petronijević, Marija (5)
Projects
No records found.

Author's Bibliography

No effect of gender on carbamazepine elimination-population approach

Vučićević, Katarina; Miljković, Branislava; Petronijević, Marija; Pokrajac, Milena; Veličković, Ružica; Mrhar, Ales; Grabnar, Iztok

(Springer, Dordrecht, 2009)

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1240
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - No effect of gender on carbamazepine elimination-population approach
VL  - 31
IS  - 1
SP  - 118
EP  - 119
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1240
ER  - 
@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Veličković, Ružica and Mrhar, Ales and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "No effect of gender on carbamazepine elimination-population approach",
volume = "31",
number = "1",
pages = "118-119",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1240"
}
Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R., Mrhar, A.,& Grabnar, I.. (2009). No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science
Springer, Dordrecht., 31(1), 118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240
Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Mrhar A, Grabnar I. No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science. 2009;31(1):118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240 .
Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Veličković, Ružica, Mrhar, Ales, Grabnar, Iztok, "No effect of gender on carbamazepine elimination-population approach" in Pharmacy World & Science, 31, no. 1 (2009):118-119,
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study

Vučićević, Katarina; Miljković, Branislava; Petronijević, Marija; Pokrajac, Milena; Mrhar, Ales; Grabnar, Iztok

(Springer, Dordrecht, 2008)

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1109
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study
VL  - 30
IS  - 5
SP  - 673
EP  - 674
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1109
ER  - 
@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2008",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study",
volume = "30",
number = "5",
pages = "673-674",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1109"
}
Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2008). Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 30(5), 673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109
Vučićević K, Miljković B, Petronijević M, Pokrajac M, Mrhar A, Grabnar I. Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science. 2008;30(5):673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109 .
Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study" in Pharmacy World & Science, 30, no. 5 (2008):673-674,
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

Pharmacist in health-care team involved in treatment of depression and anxiety

Miljković, Branislava; Vučićević, Katarina; Petronijević, Marija

(Savez farmaceutskih udruženja Srbije, Beograd, 2007)

TY  - JOUR
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Petronijević, Marija
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/953
AB  - The complexities of actions, pharmacokinetic characteristics, potential for interactions of antidepressants and anxiolitics require wide range of issues to consider in the provision of pharmaceutical care. Pharmacists have an important role to play in providing information for patients about interactions of antidepressants and anxiolitics with the other drugs, adverse reactions, duration of treatment, dosage in the context of minimum and maximum dosages, withdrawal syndrome of benzodiazepines, antidepressant discontinuation syndrome. Support of adherence to therapy, individualization of care and follow-up are important issues for pharmacists in the treatment of depression and anxiety. Pharmacists" accessibility and their expertise in the use of medicines mean that they are well placed to provide information for patients, but strategies to optimize the ability of pharmacists to perform such roles need to be developed.
AB  - S obzirom na poziciju i znanje, uloga farmaceuta je da prati bolesnika i pruži mu podršku i potrebne informacije u svim fazama terapije. Individualni pristup i praćenje pacijenta su ključni elementi za farmakoterapijski uspeh u lečenju mentalnih bolesti. Takav pristup zahteva organizaciju primarne zdravstvene zaštite zasnovanu na multidisciplinarnom sistemu u kojem farmaceuti, svojim znanjem i veštinama, kao i neposrednim kontaktom koji imaju sa pacijentom, zauzimaju značajno mesto u sprovođenju terapije i unapređenju kvaliteta života pacijenata sa depresijom i anksioznošću.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Pharmacist in health-care team involved in treatment of depression and anxiety
T1  - Farmaceut u zdravstvenom timu za terapiju depresija i anksioznosti
VL  - 57
IS  - 1-2
SP  - 10
EP  - 23
UR  - https://hdl.handle.net/21.15107/rcub_farfar_953
ER  - 
@article{
author = "Miljković, Branislava and Vučićević, Katarina and Petronijević, Marija",
year = "2007",
abstract = "The complexities of actions, pharmacokinetic characteristics, potential for interactions of antidepressants and anxiolitics require wide range of issues to consider in the provision of pharmaceutical care. Pharmacists have an important role to play in providing information for patients about interactions of antidepressants and anxiolitics with the other drugs, adverse reactions, duration of treatment, dosage in the context of minimum and maximum dosages, withdrawal syndrome of benzodiazepines, antidepressant discontinuation syndrome. Support of adherence to therapy, individualization of care and follow-up are important issues for pharmacists in the treatment of depression and anxiety. Pharmacists" accessibility and their expertise in the use of medicines mean that they are well placed to provide information for patients, but strategies to optimize the ability of pharmacists to perform such roles need to be developed., S obzirom na poziciju i znanje, uloga farmaceuta je da prati bolesnika i pruži mu podršku i potrebne informacije u svim fazama terapije. Individualni pristup i praćenje pacijenta su ključni elementi za farmakoterapijski uspeh u lečenju mentalnih bolesti. Takav pristup zahteva organizaciju primarne zdravstvene zaštite zasnovanu na multidisciplinarnom sistemu u kojem farmaceuti, svojim znanjem i veštinama, kao i neposrednim kontaktom koji imaju sa pacijentom, zauzimaju značajno mesto u sprovođenju terapije i unapređenju kvaliteta života pacijenata sa depresijom i anksioznošću.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Pharmacist in health-care team involved in treatment of depression and anxiety, Farmaceut u zdravstvenom timu za terapiju depresija i anksioznosti",
volume = "57",
number = "1-2",
pages = "10-23",
url = "https://hdl.handle.net/21.15107/rcub_farfar_953"
}
Miljković, B., Vučićević, K.,& Petronijević, M.. (2007). Pharmacist in health-care team involved in treatment of depression and anxiety. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 57(1-2), 10-23.
https://hdl.handle.net/21.15107/rcub_farfar_953
Miljković B, Vučićević K, Petronijević M. Pharmacist in health-care team involved in treatment of depression and anxiety. in Arhiv za farmaciju. 2007;57(1-2):10-23.
https://hdl.handle.net/21.15107/rcub_farfar_953 .
Miljković, Branislava, Vučićević, Katarina, Petronijević, Marija, "Pharmacist in health-care team involved in treatment of depression and anxiety" in Arhiv za farmaciju, 57, no. 1-2 (2007):10-23,
https://hdl.handle.net/21.15107/rcub_farfar_953 .

Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation

Petronijević, Marija; Pokrajac, Milena; Miljković, Branislava; Vučićević, Katarina

(Savez farmaceutskih udruženja Srbije, Beograd, 2006)

TY  - JOUR
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/737
AB  - One of fundamental investigations, that pharmaceutical industry is expected to conduct during development of pharmaceutical formulation in order to prove its efficiency and safety, is bioavailability (BA), or bioequivalence (BE) assessment. Traditional approach to this investigation entails strictly controlled, expensive and time consuming study in humans. The potential for considering drugs' in vivo behavior has been extended and new selective approach has been set by development of Biopharmaceutics Classification System (BCS) and evaluation of drug absorption according to solubility and permeability properties of the drug, as well as its dissolution from pharmaceutical preparation. Manufacturers are particularly interested in creating criteria based on BCS concept for granting waiver of BA/BE studies for Immediate Release Products (IRP), aiming for reduction of time and cost of drug development process. These criteria have been discussed at many experts' meetings lately, and regulatory agencies are expected in near future to consider proposals for changes in regulative requirements according to the results from practice. If some of them were accepted, BCS would become even more significant as a powerful tool in drug and pharmaceutical preparation development process.
AB  - U osnovi ispitivanja, koja proizvođač sprovodi tokom razvoja formulacije farmaceutskog preparata u cilju dokazivanja efikasnosti i bezbednosti, nalazi se ispitivanje biološke raspoloživosti (BR), odnosno relativne biološke raspoloživosti/biološke ekvivalentnosti (BE) preparata. Tradicionalni pristup ovom ispitivanju podrazumeva strogo kontrolisano, skupo i dugotrajno in vivo ispitivanje u ljudi. Razvojem biofarmaceutskog sistema klasifikacije (BSK) i procenom resorpcije lekovitih supstanci na osnovu njihove rastvorljivosti, permeabilnosti kroz membrane i brzine rastvaranja iz farmaceutskog preparata, proširene su mogućnosti za sagledavanje in vivo ponašanja lekova i postavljena osnova za savremeni, selektivni pristup ispitivanju BR/BE. Za proizvođače je od posebne važnosti upotreba BSK-a u postavljanju kriterijuma za oslobađanje konvencionalnih preparata od ispitivanja BR/BE (waiver of BA/BE studies), sa ciljem uštede vremena i novca u procesu razvoja leka. Ovi kriterijumi su poslednjih godina predmet brojnih stručnih rasprava i u bliskoj budućnosti očekuje se da će regulatorne agencije razmotriti predloge za izmene u regulativi zasnovane na rezultatima iz prakse. Usvajanjem nekih od njih, BSK bi dobio još veći značaj kao moćno sredstvo u procesu razvoja lekovite supstance i farmaceutskih preparata.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation
T1  - Biofarmaceutski sistem klasifikacije (BSK) kao osnova za selektivni pristup ispitivanju biološke raspoloživosti/biološke ekvivalentnosti (BA/BE) farmaceutskih preparata
VL  - 56
IS  - 1
SP  - 1
EP  - 15
UR  - https://hdl.handle.net/21.15107/rcub_farfar_737
ER  - 
@article{
author = "Petronijević, Marija and Pokrajac, Milena and Miljković, Branislava and Vučićević, Katarina",
year = "2006",
abstract = "One of fundamental investigations, that pharmaceutical industry is expected to conduct during development of pharmaceutical formulation in order to prove its efficiency and safety, is bioavailability (BA), or bioequivalence (BE) assessment. Traditional approach to this investigation entails strictly controlled, expensive and time consuming study in humans. The potential for considering drugs' in vivo behavior has been extended and new selective approach has been set by development of Biopharmaceutics Classification System (BCS) and evaluation of drug absorption according to solubility and permeability properties of the drug, as well as its dissolution from pharmaceutical preparation. Manufacturers are particularly interested in creating criteria based on BCS concept for granting waiver of BA/BE studies for Immediate Release Products (IRP), aiming for reduction of time and cost of drug development process. These criteria have been discussed at many experts' meetings lately, and regulatory agencies are expected in near future to consider proposals for changes in regulative requirements according to the results from practice. If some of them were accepted, BCS would become even more significant as a powerful tool in drug and pharmaceutical preparation development process., U osnovi ispitivanja, koja proizvođač sprovodi tokom razvoja formulacije farmaceutskog preparata u cilju dokazivanja efikasnosti i bezbednosti, nalazi se ispitivanje biološke raspoloživosti (BR), odnosno relativne biološke raspoloživosti/biološke ekvivalentnosti (BE) preparata. Tradicionalni pristup ovom ispitivanju podrazumeva strogo kontrolisano, skupo i dugotrajno in vivo ispitivanje u ljudi. Razvojem biofarmaceutskog sistema klasifikacije (BSK) i procenom resorpcije lekovitih supstanci na osnovu njihove rastvorljivosti, permeabilnosti kroz membrane i brzine rastvaranja iz farmaceutskog preparata, proširene su mogućnosti za sagledavanje in vivo ponašanja lekova i postavljena osnova za savremeni, selektivni pristup ispitivanju BR/BE. Za proizvođače je od posebne važnosti upotreba BSK-a u postavljanju kriterijuma za oslobađanje konvencionalnih preparata od ispitivanja BR/BE (waiver of BA/BE studies), sa ciljem uštede vremena i novca u procesu razvoja leka. Ovi kriterijumi su poslednjih godina predmet brojnih stručnih rasprava i u bliskoj budućnosti očekuje se da će regulatorne agencije razmotriti predloge za izmene u regulativi zasnovane na rezultatima iz prakse. Usvajanjem nekih od njih, BSK bi dobio još veći značaj kao moćno sredstvo u procesu razvoja lekovite supstance i farmaceutskih preparata.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation, Biofarmaceutski sistem klasifikacije (BSK) kao osnova za selektivni pristup ispitivanju biološke raspoloživosti/biološke ekvivalentnosti (BA/BE) farmaceutskih preparata",
volume = "56",
number = "1",
pages = "1-15",
url = "https://hdl.handle.net/21.15107/rcub_farfar_737"
}
Petronijević, M., Pokrajac, M., Miljković, B.,& Vučićević, K.. (2006). Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(1), 1-15.
https://hdl.handle.net/21.15107/rcub_farfar_737
Petronijević M, Pokrajac M, Miljković B, Vučićević K. Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation. in Arhiv za farmaciju. 2006;56(1):1-15.
https://hdl.handle.net/21.15107/rcub_farfar_737 .
Petronijević, Marija, Pokrajac, Milena, Miljković, Branislava, Vučićević, Katarina, "Biopharmaceutics classification system (BCS) as a framework for selective approach to bioavailability/bioequivalence (BA/BE) investigation" in Arhiv za farmaciju, 56, no. 1 (2006):1-15,
https://hdl.handle.net/21.15107/rcub_farfar_737 .

Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy

Vučićević, Katarina; Miljković, Branislava; Pokrajac, Milena; Petronijević, Marija

(Savez farmaceutskih udruženja Srbije, Beograd, 2005)

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Petronijević, Marija
PY  - 2005
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/600
AB  - In order to describe the behavior and activity of a drug in the body and give the quantitative relationship between "input" (given dose or dosing regimen of the drug) and "output" data of the drug (concentration or effect of the drug given), it is necessary in define a mathematical model that will show their mutual interdependence. In recent years, population approach in the analysis of pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD data has acquired great importance. Population analysis provides not only a uniform model for the population, population values of PK and/or PD parameters, but also the extent of their variability. This approach offers the possibility of identifying patients' demographical, pathophysiological, and other factors that may influence the behavior of a drug, and the identification of inter- and intraindividual variability. This paper provides the comparison of fundamental and population PK. data analyses. It offers different available statistical methods in population analysis and emphasizes the most frequently used Nonlinear Mixed Effect Approach (NONMEM). Components of NONMEM model are: structural (describes PK parameters of the drug), covariate (describes relationship between demographic and other factors, and PK parameters of the drug) and statistical model (describes inter- and intraindividual variability). It also presents explanations of important parameters in the population model. In spite of its complexity, as a consequence of complex algorithms and required knowledge in modeling process. NONMEM is an unrivalled approach in data analysis and is of great importance in all clinical phases of drug development.
AB  - Za opisivanje ponašanja i sudbine leka u organizmu potrebno je definisanje modela koji matematički daju zavisnost između "ulaznih" podataka o leku (primenjena doza leka ili režim doziranja) i "izlaznih" podataka (koncentracija ili efekt leka) u funkciji vremena. Poslednjih godina sve veći značaj ima populacioni pristup analizi farmakokinetičkih (FK), farmakodinamičkih (FD), kao i FK/FD podataka. Populacionom analizom se dobija jedinstveni model za populaciju ispitanika, populacione vrednosti F:K i/ili FD parametara, ali i stepen njihove varijabilnosti. Ovakav pristup pruža mogućnost identifikacije demografskih, patofizioloških i drugih faktora koji utiču na vrednosti parametara i identifikaciju inter- i intraindividualnih varijabilnosti. U radu je upoređena populaciona sa klasičnom FK analizom podataka, date su vrste postojećih statističkih pristupa u populacionoj analizi i stavljen je akcenat na najviše upotrebljavano Nelinearno modelovanje kombinovanih efekata (NONMEM), uz objašnjenja parametara od interesa u populacionom modelu. Osnovni elementi NONMEM modela su: strukturalni (koji opisuje osnovne FK parametre leka), kovarijatni (opisuje uticaj demografskih i ostalih karakteristika na FK parametre leka) i statistički (opisuje inter- i intraindividualnu varijabilnost), l pored svoje složenosti, zbog komplikovanih algoritama i neophodnog iskustva u modelovanju, NONMEM predstavlja neprevaziđen pristup u analizi podataka i mogućnostima koje pruža i ima veliki značaj u svim kliničkim fazama razvoja leka.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy
T1  - Karakteristike populacionog farmakokinetičkog pristupa analizi podataka i njegov značaj u razvoju i primeni lekova
VL  - 55
IS  - 5-6
SP  - 483
EP  - 496
UR  - https://hdl.handle.net/21.15107/rcub_farfar_600
ER  - 
@article{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Petronijević, Marija",
year = "2005",
abstract = "In order to describe the behavior and activity of a drug in the body and give the quantitative relationship between "input" (given dose or dosing regimen of the drug) and "output" data of the drug (concentration or effect of the drug given), it is necessary in define a mathematical model that will show their mutual interdependence. In recent years, population approach in the analysis of pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD data has acquired great importance. Population analysis provides not only a uniform model for the population, population values of PK and/or PD parameters, but also the extent of their variability. This approach offers the possibility of identifying patients' demographical, pathophysiological, and other factors that may influence the behavior of a drug, and the identification of inter- and intraindividual variability. This paper provides the comparison of fundamental and population PK. data analyses. It offers different available statistical methods in population analysis and emphasizes the most frequently used Nonlinear Mixed Effect Approach (NONMEM). Components of NONMEM model are: structural (describes PK parameters of the drug), covariate (describes relationship between demographic and other factors, and PK parameters of the drug) and statistical model (describes inter- and intraindividual variability). It also presents explanations of important parameters in the population model. In spite of its complexity, as a consequence of complex algorithms and required knowledge in modeling process. NONMEM is an unrivalled approach in data analysis and is of great importance in all clinical phases of drug development., Za opisivanje ponašanja i sudbine leka u organizmu potrebno je definisanje modela koji matematički daju zavisnost između "ulaznih" podataka o leku (primenjena doza leka ili režim doziranja) i "izlaznih" podataka (koncentracija ili efekt leka) u funkciji vremena. Poslednjih godina sve veći značaj ima populacioni pristup analizi farmakokinetičkih (FK), farmakodinamičkih (FD), kao i FK/FD podataka. Populacionom analizom se dobija jedinstveni model za populaciju ispitanika, populacione vrednosti F:K i/ili FD parametara, ali i stepen njihove varijabilnosti. Ovakav pristup pruža mogućnost identifikacije demografskih, patofizioloških i drugih faktora koji utiču na vrednosti parametara i identifikaciju inter- i intraindividualnih varijabilnosti. U radu je upoređena populaciona sa klasičnom FK analizom podataka, date su vrste postojećih statističkih pristupa u populacionoj analizi i stavljen je akcenat na najviše upotrebljavano Nelinearno modelovanje kombinovanih efekata (NONMEM), uz objašnjenja parametara od interesa u populacionom modelu. Osnovni elementi NONMEM modela su: strukturalni (koji opisuje osnovne FK parametre leka), kovarijatni (opisuje uticaj demografskih i ostalih karakteristika na FK parametre leka) i statistički (opisuje inter- i intraindividualnu varijabilnost), l pored svoje složenosti, zbog komplikovanih algoritama i neophodnog iskustva u modelovanju, NONMEM predstavlja neprevaziđen pristup u analizi podataka i mogućnostima koje pruža i ima veliki značaj u svim kliničkim fazama razvoja leka.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy, Karakteristike populacionog farmakokinetičkog pristupa analizi podataka i njegov značaj u razvoju i primeni lekova",
volume = "55",
number = "5-6",
pages = "483-496",
url = "https://hdl.handle.net/21.15107/rcub_farfar_600"
}
Vučićević, K., Miljković, B., Pokrajac, M.,& Petronijević, M.. (2005). Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 55(5-6), 483-496.
https://hdl.handle.net/21.15107/rcub_farfar_600
Vučićević K, Miljković B, Pokrajac M, Petronijević M. Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy. in Arhiv za farmaciju. 2005;55(5-6):483-496.
https://hdl.handle.net/21.15107/rcub_farfar_600 .
Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Petronijević, Marija, "Characteristics of population pharmacokinetic approach with its importance in drug development and the therapy" in Arhiv za farmaciju, 55, no. 5-6 (2005):483-496,
https://hdl.handle.net/21.15107/rcub_farfar_600 .